Analyst Price Targets — CATX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 19, 2026 10:11 am | Biren Amin | Piper Sandler | $16.00 | $5.03 | TheFly | Perspective Therapeutics initiated with an Overweight at Piper Sandler |
| January 30, 2026 11:08 am | — | H.C. Wainwright | $12.00 | $4.26 | TheFly | Perspective Therapeutics price target raised to $12 from $10 at H.C. Wainwright |
| November 21, 2025 12:26 am | David Lai | UBS | $7.00 | $2.12 | TheFly | Perspective Therapeutics price target lowered to $7 from $18 at UBS |
| October 10, 2025 10:59 am | Jeet Mukherjee | BTIG | $14.00 | $4.20 | TheFly | Perspective Therapeutics initiated with a Buy at BTIG |
| October 24, 2024 3:50 am | David Dai | UBS | $20.00 | $11.69 | StreetInsider | UBS Starts Perspective Therapeutics Inc (CATX) at Buy |
| October 14, 2024 6:07 am | Jeff Jones | Oppenheimer | $22.00 | $12.66 | StreetInsider | Oppenheimer Reiterates Outperform Rating on Perspective Therapeutics Inc (CATX) |
| September 25, 2024 6:10 am | Nicole Germino | Truist Financial | $21.00 | $12.28 | StreetInsider | Truist Securities Starts Perspective Therapeutics Inc (CATX) at Buy |
| July 25, 2024 6:11 am | Alec Stranahan | Bank of America Securities | $24.00 | $12.82 | TheFly | Perspective Therapeutics initiated with a Buy at BofA |
| June 18, 2024 7:26 am | Jeff Jones | Oppenheimer | $19.00 | $11.93 | StreetInsider | Perspective Therapeutics Inc (CATX) PT Raised to $19 at Oppenheimer |
| June 14, 2024 6:20 am | Gregory Renza | RBC Capital | $3.00 | $1.15 | StreetInsider | RBC Capital Reiterates Outperform Rating on Perspective Therapeutics Inc (CATX) |
Latest News for CATX
/PRNewswire/ -- Equity-Insider.com News Commentary - More than 2,100 oncology clinical trials were initiated globally in 2024, with targeted therapies
SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will report its full year 2025 financial results and provide a business update on Monday, March 16, 2025 after the market closes. The press release will be…
Perspective Therapeutics (NASDAQ: CATX - Get Free Report) and Profusa (NASDAQ: PFSA - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, institutional ownership, earnings and profitability. Insider and Institutional Ownership 54.7% of Perspective…
SEATTLE, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today announced the pricing of an underwritten offering of 39,576,088 shares of its common stock at an offering price of $3.79 per share and, to certain investors in lieu of common stock,…
Biosig Technologies (NASDAQ: STEX - Get Free Report) and Perspective Therapeutics (NASDAQ: CATX - Get Free Report) are both small-cap manufacturing companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, valuation and dividends. Valuation and Earnings This table compares Biosig
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CATX.
U.S. House Trading
No House trades found for CATX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.